Youssef Dairi, MD
Pulmonary Disease · New Albany, INNPI 1295875417
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (48.8%), education and travel and lodging — rather than concentrated in one kind of arrangement. 29 manufacturers reported payments, led by Intuitive Surgical at 48.2% of the total. Reporting peaked in 2023 at $8,221 and has fallen 65.6% since, to $2,827 in 2025.
Across 407 payments — averaging $34.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$7K
- AstraZeneca$1K
- GSK$1K
- Boehringer Ingelheim$586
- Insmed, Inc.$493
- Harmony Biosciences LLC$453
- plus $3K from 23 others
What the payments were for
- Travel & lodging$7385%
- Food & beverage$6,82249%
- Education$6,43046%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 5 | $6,738 |
| AstraZeneca | 68 | $1,304 |
| GSK | 81 | $1,218 |
| Boehringer Ingelheim | 37 | $586 |
| Insmed, Inc. | 32 | $493 |
| Harmony Biosciences LLC | 18 | $453 |
| Takeda Pharmaceuticals U.S.A., Inc. | 20 | $381 |
| Actelion Pharmaceuticals US, Inc. | 15 | $332 |
| Amgen | 18 | $292 |
| Sanofi | 13 | $262 |
| Regeneron Healthcare Solutions, Inc. | 13 | $258 |
| Verona Pharma, Inc. | 20 | $251 |
| Mylan Specialty L.p. | 11 | $239 |
| Viatris Specialty LLC | 8 | $164 |
| Jazz Pharmaceuticals Inc. | 5 | $163 |
| Sanofi-aventis U.S. LLC | 2 | $155 |
| Baxter Healthcare | 6 | $108 |
| Mallinckrodt Hospital Products Inc. | 6 | $103 |
| Axsome Therapeutics, Inc. | 6 | $96 |
| Vifor Pharma, Inc. | 5 | $91 |
| Philips North America LLC | 5 | $81 |
| Idorsia Pharmaceuticals US Inc | 3 | $54 |
| Inspire Medical Systems, Inc. | 2 | $44 |
| Inogen, Inc. | 3 | $39 |
| Mayne Pharma Commercial LLC | 1 | $19 |
| Merck | 1 | $19 |
| Pulmonx Corporation | 1 | $17 |
| Electromed, Inc. | 1 | $15 |
| Liquidia Technologies, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$3,719
- ION$3,000
How this compares
$13,990 in reported general payments places this provider in the 85th percentile of 258 pulmonary disease providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 24 | $312,183 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 35 | $37,616 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 20 | $24,593 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 32 | $18,166 |
| Breo ElliptaFluticasone/Vilanterol | 36 | $14,379 |
| Spiriva RespimatTiotropium Bromide | 17 | $12,946 |
| Spiriva HandihalerTiotropium Bromide | 13 | $8,506 |
| Atrovent HfaIpratropium Bromide | 12 | $5,566 |
| Advair HfaFluticasone Propion/Salmeterol | 13 | $5,438 |
| BreynaBudesonide/Formoterol Fumarate | 18 | $2,910 |
| Theophylline ErTheophylline Anhydrous | 42 | $2,367 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 92 | $2,004 |
| Ventolin HfaAlbuterol Sulfate | 21 | $1,138 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 14 | $859 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 16 | $579 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat | $586 | $343,29573 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $1,218 | $51,99571 claims |
| AstraZenecaBreztri Aerosphere | $1,304 | $24,59320 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 258 pulmonary disease providers in Indiana.
Other pulmonary disease in New Albany
- David MaresAnderson$1.3M
- David WilsonSeymour$689K
- Giovanni InfusinoCrown Point$526K
- Ajay DeshpandeTerre Haute$304K
- Faisal KhanGreenwood$207K
- Sandeep KukrejaGreenwood$206K
- Raja DevanathanHobart$193K
- Asaad JandaliMunster$161K
- Gaurav KumarPortage$102K
- Rajeev MehtaMuncie$88K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.